Abstract
In 2015 the results of several clinical studies were published on cardiovascular safety of antidiabetics in patients with type-2 diabetes. On the one hand, the studies demonstrated the safety of new therapies (sitagliptin, lixisenatide, insulin glargine), but they provided, on the other, unexpected results as well - reduced mortality rate in the population of patients with type-2 diabetes at high risk (empagliflozin ).
The contribution of studies providing new evidence on drug safety or new signals of unexpected benefit (EMPA-REG OUTCOME) consists mainly in the fact that they initiate the process of more detailed analysis of the mechanisms of effects of antidiabetics, necessitate revision of current procedures and offer suggestions of better treatment strategies.